Thank You For Your Interest – Please Complete the Download Form

WP227 Boehringer Ingelheim: From Underdog To Giant
To weather the 2009-2010 economy, Boehringer Ingelheim kept a close eye on the global financial markets while utilizing cost-economizing activities, such as restructuring. But unlike other pharmas and biotechs, the company’s entrance into the diabetes market was a restructuring that involved neither layoffs nor cuts in R&D and licensing expenditures. The company set a prominent example to other diabetes drug manufacturers.

Download White Paper

Our complimentary white papers draw on our primary research findings to provide you information on critical life sciences topics.

Asterisks (*) indicate required fields.

If you have any problems filling out the form, please contact Heather Corcoran at 919-433-0215.